global pharmaceutical and biotechnology outlook mature biotech | research report

Report: Global Pharmaceutical & Biotechnology Outlook 2013: Mature Biotech

Category: Healthcare

www.researchonglobalmarkets.com

Insert Image Height - 3.60 Width – 4.98

http://bit.ly/biotechnology-mature-biotech


http://www.researchonindia.com/

http://www.researchonglobalmarkets.com/

https://www.facebook.com/pages/Research-on-Global-Markets/536186973101152

http://www.linkedin.com/groups?gid=5131467&mostPopular=&trk=tyah

https://twitter.com/researchonglobe


• Publish date: 2nd Jan, 2013

• Number of slides: 110

• Geographic coverage: Global

• Available format: PDF, CD, Hardcopy

• Price for Single User License: USD 2,500

• Price for Site License: USD 5,000

• Price for Global Site License: 7,500

• Delivery Time: Within 1 business day

• Payment Modes: Credit/Debit Card, RTGS/Wire Transfer, Google

Wallet, PayPal

Report Details









• Profitable biotech (Mature biotech) and non-profitable biotech

companies (Rising stars) have developed innovative drugs for

treatment of chronic and non chronic diseases

• In the next five years the distinction between mature biotech

companies and large global pharma is likely to disappear as

investment in R&D and acquisition start delivering and market cap

match the large global pharma

• Dividend and consolidation could be the future drivers and continue

to attract long term investors

• Optimism prevails around the future of this sector as a whole which

was reflected in the unprecedented rally in shares in 2012

Report Insights









• This trend is expected to continue in the next five year driven by

launch of Innovative drugs catering to unmet needs in Alzheimers,

HCV, osteoporosis, RA, Psoriasis, MS, Dyslipidemia, Cystic fibrosis,

Cancer and orphan diseases

• Drug approvals and label expansion of existing portfolio of launched

drugs and data from late stage pipeline drugs should maintain the

growth momentum and investors interest

• 2012 was recovering from the big acquisitions made in the last five

years by this sector but we expect exercising of some restrain for

similar large acquisitions as investors would like to see the returns

reflected in the top-line and EPS

Report Insights (Continued)









• However in-licensing of early or mid stage compounds or small

acquisitions will continue since the rising stars will keep throwing the

bait by taking risks and innovate using novel technology platforms or

validating novel targets for treating diseases

• Patent expiry impact is modest for the next five years for the sector

as majority have not so easy to copy biologics and other drugs in

their portfolio

• The optimism of biosimilar players is reflected in the maturing

pipeline

• Para IV filing from other generic players continues to pour leaving

room for surprises and volatility

Report Insights (Continued)









• In depth analyses of biotech companies, their launched drug

portfolio and promising drug candidates in the pipeline is provided

• Current competitive landscape of the targeted therapy areas and the

innovative strategy each company is deploying to create or retain its

leadership in the therapy areas has been discussed

• Forecast for major marketed drugs and drugs in the pipeline are

included

• Risk reward analyses of important upcoming milestones of the

companies are included which should help fund managers as well as

pharma company management to make critical decisions

Report Coverage









• Macro Analysis

• Merger & Acquisitions Forecast (2013-2020)

• Industry Tables

Table of Contents









Interested in this report?

About Us Research on Global Markets is a leading source for market research on various sectors globally offering premium research content from worldwide publishers of market research reports

For further information, get in touch with us:

E-mail: [email protected] Call: US: +1 866 325 7446 UK: +44 203 514 2363 Others: +91 22 4098 7600

Industry Segments

Automotive & Transport Consumer goods Agriculture

Food and Beverage Energy and Utilities Public Sector

Manufacturing & Construction Healthcare Media & Entertainment

IT, Telecom & Electronics Services Others

To view more details regarding this premium market research report, Please click here







global pharmaceutical and biotechnology outlook mature biotech | research report

Documents